From bench to bedside: A roadmap to emerging TB therapeutics

Sarika  Thakur; Alka Sharma; Ram Upadhyaya; Inderjeet Kaur; Ram Gopal Nitharwal

doi:10.62110/sciencein.cbl.2025.v12.1278

Authors

Sarika Thakur Central University of Haryana https://orcid.org/0000-0002-1849-0875
Alka Sharma Central University of Haryana https://orcid.org/0000-0002-7669-4032
Ram Upadhyaya Maharaja Surajmal Brij University, Bharatpur https://orcid.org/0000-0001-7338-7486
Inderjeet Kaur Central University of Haryana https://orcid.org/0000-0001-8778-1396
Ram Gopal Nitharwal Central University of Haryana https://orcid.org/0000-0002-7507-8350

DOI:

https://doi.org/10.62110/sciencein.cbl.2025.v12.1278

Keywords:

Tuberculosis, Antibiotic resistance, drug discovery, Anti-TB therapy, new drugs for TB, Emerging drugs for TB, TB drugs in clinical trials, drug targets for TB, Tuberculosis drug mechanism

Abstract

Tuberculosis (TB) has persistently posed a formidable challenge throughout human history as a contagious disease. Despite the gravity of the global TB burden, the advancement of available therapeutic treatment has been minimal over several decades. The emergence of drug-resistant M. tb has diminished the efficacy of existing treatments. Given the escalating global TB crisis, expediting the drug discovery process is paramount, demanding the development of novel drugs capable of eliminating the drug-resistant as well as latent TB infections. Furthermore, the new drugs should shorten the duration of treatment. This article summarises the current landscape of tuberculosis treatment options, shedding light on the latest efforts in the drug discovery process. This review also delves into various molecular pathways of the mycobacterium in order to ascertain unique drug targets along with their latest novel inhibitors, thus providing a comprehensive platform for the readers.